Saint Luke's Mid America Heart Institute, Kansas City, MO, USA; University of Missouri Kansas City, MO, USA.
AstraZeneca, Gaithersburg, MD, USA.
Indian Heart J. 2022 Sep-Oct;74(5):398-405. doi: 10.1016/j.ihj.2022.07.008. Epub 2022 Aug 2.
We sought to describe global patterns in achievement of risk factor control for primary prevention in patients with T2D and explore the association of country's GNI/capita with risk factor control.
The DISCOVER study is a prospective, observational study of patients with T2D from 38 countries enrolled at initiation of second-line glucose-lowering therapy. We examined achievement of risk factor control (glycosylated hemoglobin <7%, blood pressure <140/90 mmHg, prescription of a statin) at 3 years among those without optimal control at baseline. Countries were stratified by gross national income (GNI)/capita, from 2017). We examined the impact of country GNI/capita with achievement of risk factor control.
Our cohort included 9613 patients with T2D and without baseline cardiovascular disease (mean age 57.2 ± 8.7 years, 47.9% women). At baseline, 6354/7646 patients (83.1%) had suboptimal glucose control, 3449/9200 patients (37.5%) had suboptimal BP control, and 2800/4221 patients (66.7%) were not on an appropriate statin (sample sizes differed due to missing covariate data). Optimal control at 3 years of follow-up was achieved in 41% (glucose), 56% (blood pressure), and 29% (statins) of patients. There was significant variability in achievement of risk factor control across countries but no association between country GNI/capita with achievement of risk factor control (p > 0.08 for all).
In a global, prospective study of patients with T2D, we found that cardiovascular risk factor control achievement was suboptimal despite 3 years of follow-up in specialized health care systems. Neither country-level nor patient-level socioeconomic factors fully explained this finding.
我们旨在描述 T2D 患者一级预防中危险因素控制的全球模式,并探讨国家人均国民总收入(GNI)与危险因素控制的关系。
DISCOVER 研究是一项前瞻性、观察性研究,纳入了来自 38 个国家的在开始二线降糖治疗时未达到最佳血糖控制的 T2D 患者。我们检查了在基线时未达到最佳控制的患者在 3 年内是否达到了危险因素控制(糖化血红蛋白<7%,血压<140/90mmHg,处方他汀类药物)。根据 2017 年的国民总收入(GNI)/人均收入,将国家分层。我们检查了国家 GNI/人均收入对危险因素控制的影响。
我们的队列包括 9613 名无基线心血管疾病的 T2D 患者(平均年龄 57.2±8.7 岁,47.9%为女性)。基线时,6354/7646 例(83.1%)患者血糖控制不理想,3449/9200 例(37.5%)血压控制不理想,2800/4221 例(66.7%)未服用适当的他汀类药物(由于缺失协变量数据,样本量有所不同)。在 3 年的随访中,41%(血糖)、56%(血压)和 29%(他汀类药物)的患者达到了最佳控制。尽管在专业医疗保健系统中进行了 3 年的随访,但各国之间在实现危险因素控制方面存在显著差异,但国家 GNI/人均收入与危险因素控制之间无关联(所有结果 p>0.08)。
在一项针对 T2D 患者的全球性、前瞻性研究中,我们发现,尽管在专业医疗保健系统中进行了 3 年的随访,但心血管危险因素控制的达标率仍不理想。国家层面和患者层面的社会经济因素都不能完全解释这一发现。